VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Entry into a Material Definitive Agreement

VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

(d) Exhibits.


ViewRay, Inc. Exhibit
EX-5.1 2 d538874dex51.htm EX-5.1 EX-5.1    New York Northern California Washington DC São Paulo London    ParisMadridTokyoBeijingHong Kong     Davis Polk & Wardwell LLP 1600 El Camino Real Menlo Park,…
To view the full exhibit click here

About VIEWRAY, INC. (NASDAQ:VRAY)

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

An ad to help with our costs